PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
Items 201–300 of 1,000
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes
Tang, C., & Oram, J. F. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.03.011 · Cited by 121
Li, D., Wang, D., Wang, Y., Ling, W., Feng, X., & Xia, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.159772 · Cited by 115
Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome
Prieur, X., Rőszer, T., & Ricote, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.017 · Cited by 129
Marleau, S., Harb, D., Bujold, K., Avallone, R., Iken, K., Wang, Y., Demers, A., Sirois, M. G., Febbraio, M., Silverstein, R. L., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3253fje · Cited by 115
Liver X Receptors Downregulate 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity
Stulnig, T. M., Oppermann, U., Steffensen, K. R., Schuster, G. U., & Gustafsson, J.-A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2426 · Cited by 115
Ppars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 129
Self-citationMetabolic syndrome: the danger signal in atherosclerosis
Mathieu, P., Pibarot, P., & Despres, J.-P. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.285 · Cited by 114
Roles and regulation of microglia activity in multiple sclerosis: insights from animal models
Distéfano‐Gagné, F., Bitarafan, S., Lacroix, S., & Gosselin, D. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00709-6 · Cited by 119
Molecular regulation of macrophage reverse cholesterol transport
Wang, X., & Rader, D. J. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3281ec5113 · Cited by 113
Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 126
“Effects on cholesterol transporters ABCA1 PPARα activators induce cholesterol removal from human macrophages through stimulation of ABCA1[36] (not yet investigated for fenofibrate) SR-B1 (homologous with the human CLA-1 scavenger receptor) SR-B1/CLA-1 have a high affinity for HDL and fenofibrate increases SR-B1 expres…”
BackgroundPeroxisome Proliferator-Activated Receptor α Reduces Cholesterol Esterification in Macrophages
Chinetti, G., Lestavel, S., Fruchart, J.-C., Clavey, V., & Staels, B. (2003) · Circulation Research · doi:10.1161/01.res.0000053386.46813.e9 · Cited by 113
Self-citationCherkaoui‐Malki, M., Meyer, K., Wq, C., Latruffe, N., Yeldandi, A. V., Rao, M. S. R., Bradfield, C. A., & Reddy, J. K. (2001) · Gene Expression · doi:10.3727/000000001783992533 · Cited by 122
“Requirement for the extracellular domain of CD36.”
BackgroundInfluentialNaringenin and Atherosclerosis: A Review of Literature
Orhan, İ. E., Nabavi, S. F., Daglia, M., Tenore, G. C., Mansouri, K., & Nabavi, S. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666141202110216 · Cited by 116
“resulting in atheroprotective role [115, 116].”
Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPARγ-LXRα-ABCA1/ABCG1 pathway
Zheng, S., Huang, H., Li, Y., Wang, Y., Zheng, Y., Liang, J., Zhang, S., Liu, M., & Fang, Z. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105639 · Cited by 122
Ljung, B., Bamberg, K., Dahllöf, B., Kjellstedt, A., Oakes, N. D., Östling, J., Svensson, L., & Camejo, G. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200127-jlr200 · Cited by 109
“centred effects of PPAR agonists on FA and lipoprotein metabolism and the established actions of PPAR agonists on FA metabolism and improved insulin sensitivity have led to the hypothesis that substances with combined PPAR / effects could be superior to the individual specific ligands for the treatment of insulin resi…”
BackgroundThe Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis
Xu, P., Zhai, Y., & Wang, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041260 · Cited by 108
Ruan, X. Z., Moorhead, J. F., Fernando, R., Wheeler, D. C., Powis, S. H., & Varghese, Z. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000050414.52908.da · Cited by 109
Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors
Berger, J., & Wagner, J. A. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007381 · Cited by 108
“81 In addition, two recent studies have suggested that either PPAR a 82 or PPAR g 82,83 activation in macrophages can induce the expression of a cholesterol efflux “pump” protein.”
Wu, C., Luan, H., Zhang, X., Wang, S., Zhang, X., Sun, X., & Guo, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095452 · Cited by 106
Coagulation and atherothrombotic disease
Ajjan, R., & Grant, P. J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.042 · Cited by 118
The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective
Krolikoski, M., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.007 · Cited by 111
Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1
Oram, J. F. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02289-x · Cited by 113
Ozasa, H., Ayaori, M., Iizuka, M., Terao, Y., Uto‐Kondo, H., Yakushiji, E., Takiguchi, S., Nakaya, K., Hisada, T., Uehara, Y., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.113 · Cited by 110
Chinetti, G., Fruchart, J.-C., & Staels, B. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200310000-00006 · Cited by 103
Self-citationPPARs and the kidney in metabolic syndrome
Ruan, X. Z., Zheng, F., & Guan, Y. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00152.2007 · Cited by 110
Chinetti, G., Fruchart, J., & Staels, B. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.11.004 · Cited by 112
Self-citationEmerging Role of Mast Cells and Macrophages in Cardiovascular and Metabolic Diseases
Xu, J., & Shi, G. (2012) · Endocrine Reviews · doi:10.1210/er.2011-0013 · Cited by 113
Harari, A., Harats, D., Marko, D., Cohen, H., Barshack, I., Kamari, Y., Gonen, A., Gerber, Y., Ben‐Amotz, A., & Shaish, A. (2008) · Journal of Nutrition · doi:10.1093/jn/138.10.1923 · Cited by 112
Clinical interest of PPARs ligands
Vergès, B. L. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70083-6 · Cited by 112
Nuclear receptor signaling in macrophages
Valledor, A. F., & Ricote, M. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.10.016 · Cited by 117
Insulin Clearance and the Incidence of Type 2 Diabetes in Hispanics and African Americans
Lee, C. C., Haffner, S. M., Wagenknecht, L. E., Lorenzo, C., Norris, J. M., Bergman, R. N., Stefanovski, D., Anderson, A. M., Rotter, J. I., Goodarzi, M. O., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1316 · Cited by 101
PPAR-α effects on the heart and other vascular tissues
Francis, G. A., Annicotte, J.-S., & Auwerx, J. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01118.2002 · Cited by 100
Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328333645a · Cited by 113
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Duffy, D., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.105.593855 · Cited by 98
Activation of transcription factors and gene expression by oxidized low-density lipoprotein
Mazière, C., & Mazière, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.024 · Cited by 109
Induction of Human Liver X Receptor α Gene Expression Via an Autoregulatory Loop Mechanism
Li, Y., Bolten, C., Bhat, B. G., Woodring-Dietz, J., Li, S., Prayaga, S. K., Xia, C., & Lala, D. S. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.3.0789 · Cited by 96
Soumian, S., Albrecht, C., Davies, A. H., & Gibbs, R. G. J. (2005) · Vascular Medicine · doi:10.1191/1358863x05vm593ra · Cited by 115
Seo, M., Inoue, I., Tanaka, M., Matsuda, N., Nakano, T., Awata, T., Katayama, S., Alpers, D., & Komoda, T. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2879-3 · Cited by 99
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
van der Hoogt, C. C., de Haan, W., Westerterp, M., Hoekstra, M., Dallinga-Thie, G. M., Romijn, J. A., Princen, H. M. G., Jukema, J. W., Havekes, L. M., & Rensen, P. C. N. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700108-jlr200 · Cited by 95
The Nuclear Hormone Receptor PPARγ as a Therapeutic Target in Major Diseases
Schmidt, M., Brüne, B., & von Knethen, A. (2010) · TheScientificWorldJournal · doi:10.1100/tsw.2010.213 · Cited by 111
Regulation of lipid droplet-associated proteins by peroxisome proliferator-activated receptors
Rodriguez, M. A. D. L. R., & Kersten, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.07.007 · Cited by 105
The Activity of PPARγ in Primary Human Trophoblasts Is Enhanced by Oxidized Lipids
Schild, R. L., Schaiff, W. T., Carlson, M. G., Cronbach, E. J., Nelson, D. M., & Sadovsky, Y. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8284 · Cited by 91
Millatt, L. J., Bocher, V., Fruchart, J., & Staels, B. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00366-9 · Cited by 107
Self-citationSugawara, A., Uruno, A., Kudo, M., Ikeda, Y., Sato, K., Taniyama, Y., Ito, S., & Takeuchi, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104560200 · Cited by 102
NICHOLSON, A. C. (2004) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2003.09.004 · Cited by 107
Berger, A., Mutch, D. M., German, J. B., & Roberts, M. (2002) · Lipids in Health and Disease · doi:10.1186/1476-511x-1-2 · Cited by 91
Majdalawieh, A., & Ro, H.-S. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08004 · Cited by 90
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
“• increasing cell cholesterol efflux secondary to an induction of cell ABCA1 expression [218]”
BackgroundWallace, J. M., Schwarz, M., Coward, P., Houze, J. B., Sawyer, J. K., Kelley, K. L., Chai, A., & Rudel, L. L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500002-jlr200 · Cited by 94
Park, S., Ahn, J. W., Jo, Y., Kang, H.-Y., Kim, H. J., Cheon, Y., Kim, J. W., Park, Y., Lee, S., & Park, K. (2020) · ACS Nano · doi:10.1021/acsnano.9b07993 · Cited by 87
Babaev, V. R., Ishiguro, H., Ding, L., Yancey, P. G., Dove, D. E., Kovacs, W. J., Semenkovich, C. F., Fazio, S., & Linton, M. F. (2007) · Circulation · doi:10.1161/circulationaha.106.684704 · Cited by 86
Rubic, T., & LORENZ, R. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.10.018 · Cited by 102
The monocyte/macrophage as a therapeutic target in atherosclerosis
Saha, P., Modarai, B., Humphries, J., Mattock, K., Waltham, M., Burnand, K. G., & Smith, A. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.017 · Cited by 103
Kok, T., Wolters, H., Bloks, V. W., Havinga, R., Jansen, P. L. M., Staels, B., & Kuipers, F. (2003) · Gastroenterology · doi:10.1053/gast.2003.50007 · Cited by 91
Self-citationPeroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis
Lee, C., & Evans, R. M. (2002) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(02)00668-9 · Cited by 94
Kiss, R. S., McManus, D. C., Franklin, V., Tan, W. L., McKenzie, A., Chimini, G., & Marcel, Y. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300137200 · Cited by 86
Wang, S., Wu, D., Matthan, N. R., Lamon‐Fava, S., Lecker, J. L., & Lichtenstein, A. H. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.024 · Cited by 99
Lycopene regulation of cholesterol synthesis and efflux in human macrophages
Palozza, P., Simone, R. E., Catalano, A., Parrone, N., Monego, G., & Ranelletti, F. O. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.08.010 · Cited by 91
“[17,18].”
Interleukin-10 Facilitates Both Cholesterol Uptake and Efflux in Macrophages
Han, X., Kitamoto, S., Lian, Q., & Boisvert, W. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040899 · Cited by 84
Ren, K., Li, H., Zhou, H.-F., Liang, Y., Tong, M., Chen, L., Zheng, X.-L., & Zhao, G.-J. (2019) · Aging · doi:10.18632/aging.102498 · Cited by 83
Wang, Z., Dong, Z., Yang, Y., Wang, J., Yang, T., Chen, X., Liang, L., & Mu, W. (2021) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2021.103161 · Cited by 93
Metabolic Programming of Macrophages: Implications in the Pathogenesis of Granulomatous Disease
Wilson, J. L., Mayr, H. K., & Weichhart, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02265 · Cited by 91
Shaish, A., Harari, A., Hananshvili, L., Cohen, H., Bitzur, R., Luvish, T., Ulman, E., Golan, M., Ben‐Amotz, A., Gavish, D., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.12.004 · Cited by 83
Macrophage-specific inhibition of NF-κB activation reduces foam-cell formation
Ferreira, V., van Dijk, K. W., Groen, A. K., Vos, R. M., van der Kaa, J., Gijbels, M. J., Havekes, L. M., & Pannekoek, H. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.07.018 · Cited by 82
Liver X receptors in cardiovascular and metabolic disease
Geyeregger, R., Zeyda, M., & Stulnig, T. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5398-3 · Cited by 91
Patel, D. C., Albrecht, C., Pavitt, D., Paul, V., Pourreyron, C., Newman, S. P., Godsland, I. F., Valabhji, J., & Johnston, D. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022142 · Cited by 81
PPAR agonists in the treatment of atherosclerosis
Francis, G. A., Annicotte, J.-S., & Auwerx, J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00014-6 · Cited by 88
Thomas, A. W., Davies, N. A., Moir, H., Watkeys, L., Ruffino, J. S., Isa, S. A., Butcher, L. R., Hughes, M. G., Morris, K., & Webb, R. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00864.2011 · Cited by 80
“In these subjects, beneficial alterations were observed in serum lipid profiles (increased HDL-cholesterol and decreased total cholesterol, LDL-cholesterol, and triglycerides), with increased HDL-cholesterol correlating with PPAR target gene expression, indicating that exercise had enhanced reverse cholesterol transpo…”
BackgroundInfluentialMalerød, L., Sporstøl, M., Juvet, L. K., Mousavi, A., Gjøen, T., & Berg, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00819-2 · Cited by 89
PPARγ and metabolism: insights from the study of human genetic variants
Gurnell, M. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01767.x · Cited by 89
“…of the ATP-binding cassette transporter A1 (ABCA1), a reverse cholesterol transporter (and key mediator of cholesterol efflux from macrophages; reviewed in Tall et al., 2002) has also been shown to be a PPARγ target gene in human and mouse macrophages (Chawla et al., 2001; Chinetti et al., 2001).”
Peroxisome Proliferator-Activated Receptor .GAMMA. and Cardiovascular Diseases
Takano, H., & Komuro, I. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1071 · Cited by 89
Östberg, T., Svensson, S., Selén, G., Uppenberg, J., Thor, M., Sundbom, M., Sydow‐Báckman, M., Gustavsson, A., & Jendeberg, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401552200 · Cited by 85
Lipids and the immune response: from molecular mechanisms to clinical applications
Yaqoob, P. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200303000-00002 · Cited by 88
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 82
HDL Cholesterol: Physiology, Pathophysiology, and Management
Link, J. J., Rohatgi, A. K., & de Lemos, J. A. (2007) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2007.01.004 · Cited by 95
Ditiatkovski, M., Toh, B.-H., & Bobik, A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238357.60338.90 · Cited by 79
Clément, M., Basatemur, G., Masters, L., Baker, L., Bruneval, P., Iwawaki, T., Kneilling, M., Yamasaki, S., Goodall, J., & Mallat, Z. (2016) · Circulation · doi:10.1161/circulationaha.116.022668 · Cited by 79
Gbaguidi, F. G., Chinetti, G., Milosavljevic, D., Teissier, E., Chapman, J., Olivecrona, G., Fruchart, J. C., Griglio, S., Fruchart-Najib, J., & Staels, B. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02223-8 · Cited by 79
Self-citationLi, F., Patterson, A. D., Krausz, K. W., Tanaka, N., & Gonzalez, F. J. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m027433 · Cited by 78
Resveratrol in Cholesterol Metabolism and Atherosclerosis
Voloshyna, I., Hussaini, S. M. A., & Reiss, A. B. (2012) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0025 · Cited by 82
Kooistra, T., Verschuren, L., de Vries-van der Weij, J., Koenig, W., Toet, K., Princen, H. M. G., & Kleemann, R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238348.05028.14 · Cited by 78
Arakawa, R., Tamehiro, N., Nishimaki-Mogami, T., Ueda, K., & Yokoyama, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000163844.07815.c4 · Cited by 78
Jiang, T., Ren, K., Chen, Q., Li, H., Yao, R., Hu, H., Lv, Y.-C., & Zhao, G.-J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484031 · Cited by 87
GPR109A and Vascular Inflammation
Chai, J. T., Digby, J. E., & Choudhury, R. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0325-9 · Cited by 82
PPARγ and LXR Signaling Inhibit Dendritic Cell-Mediated HIV-1 Capture and trans-Infection
Hanley, T. M., Puryear, W. B., Gummuluru, S., & Viglianti, G. A. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000981 · Cited by 85
Lin, X., Hu, H., Liu, Y., Hu, X., Fan, X., Zou, W.-W., Pan, Y., Zhou, W., Peng, M.-W., & Gu, C. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2949 · Cited by 77
Siri, P., Candela, N., Zhang, Y.-L., Ko, C., Eusufzai, S., Ginsberg, H. N., & Huang, L.-S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108909200 · Cited by 77
Li, A. C., & Palinski, W. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141247 · Cited by 86
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Cholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 83
Fu, Y., Luo, L., Luo, N., & Garvey, W. T. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.041 · Cited by 80
Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo
Rosignoli, C., Nicolas, J. C., Jomard, A., & Michel, S. (2003) · Experimental Dermatology · doi:10.1034/j.1600-0625.2003.00014.x · Cited by 77
Cholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 94
Hennuyer, N., Tailleux, A., Torpier, G., Mezdour, H., Fruchart, J.-C., Staels, B., & Fiévet, C. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000175756.56818.ee · Cited by 76
Self-citationIkewaki, K., Tohyama, J.-I., Nakata, Y., Wakikawa, T., Kido, T., & Mochizuki, S. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.278 · Cited by 76
Cha, D. R., Zhang, X., Zhang, Y., Wu, J., Su, D., Han, J. Y., Fang, X., Yu, B., Breyer, M. D., & Guan, Y. (2007) · Diabetes · doi:10.2337/db06-1134 · Cited by 76
CD36, oxidized LDL and PPARγ: pathological interactions in macrophages and atherosclerosis
NICHOLSON, A. C., & Hajjar, D. P. (2004) · Vascular Pharmacology · doi:10.1016/j.vph.2004.08.003 · Cited by 88
Glucose Regulates the Transcription of Human Genes Relevant to HDL Metabolism
Tu, A.-Y., & Albers, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1851 · Cited by 84
Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor
Wu, K. K., Wu, T.-J., Chin, J., Mitnaul, L. J., Hernandez, M., Cai, T., Ren, N., Waters, M. G., Wright, S. D., & Cheng, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.029 · Cited by 77
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.